Article | Published:

Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin)

Abstract

Background

To assess the efficacy of combined 5FU and Avastin injections in the treatment of primary pterygium

Methods

Sixteen eyes with primary pterygium received intralesional 5 fluorouracil and Avastin (2.5–5 mg) injections every 2 weeks for a maximum of five injections. Fourteen eyes of 14 patients received five injections, one eye received three injections and one eye received two injections. All eyes were followed at monthly intervals for 3 months after last injection. Tissue was obtained by surgical excision of primary pterygium from four eyes who received injections and three eyes with primary pterygium who did not receive injections (control) and subjected to immunohistological examination for beta fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), von-Willebrand factor (vWF), lymphatic vessel endothelial hyaluronan receptor (LYVE-1) and collagen-I.

Results

Pterygium progression was arrested in all patients. Sixty-two percent of patients had improvement of redness while 89% had reduced thickness of the lesion. VEGF, bFGF, EGF, vWF, LYVE-1 and collagen-I were all reduced in the injected samples.

Conclusions

The injection of 5 fluorouracil and Avastin act synergistically to arrest progression and induce atrophy in primary pterygium. This is related to the effect of agents on fibroblasts, collagen, and vascular tissues. Such medical intervention is a safe and viable option in the management of primary pterygium though excision of residual tissue is still required in some cases. Longer follow up is needed to ascertain whether this will reduce the recurrence rate following excision.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kim KW, Park SH, Kim JC. Fibroblast biology in pterygia. Exp Eye Res. 2016;142:32–9.

  2. 2.

    Detorakis ET, Spandidos DA. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review). Int J Mol Med. 2009;23:439–47.

  3. 3.

    Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28:468–70.

  4. 4.

    Mauro J, Foster CS. Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol. 2009;24:130–4.

  5. 5.

    Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004;23:195–228.

  6. 6.

    Gumus K, Karakucuk S, Mirza GE, Akgun H, Arda H, Oner AO. Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate. Br J Ophthalmol. 2014;98:796–800.

  7. 7.

    Ling S, Li Q, Lin H, Li W, Wang T, Ye H, et al. Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium. Eye. 2012;26:1451–8.

  8. 8.

    Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14:608–16.

  9. 9.

    Riordan-Eva P, Kielhorn I, Ficker LA, Steele AD, Kirkness CM. Conjunctival autografting in the surgical management of pterygium. Eye. 1993;7:634–8.

  10. 10.

    Kheirkhah A, Hashemi H, Adelpour M, Nikdel M, Rajabi MB, Behrouz MJ. Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft. Ophthalmology. 2012;119:227–32.

  11. 11.

    Said DG, Faraj LA, Elalfy MS, Yeung A, Miri A, Fares U, et al. Intra-lesional 5 fluorouracil for the management of recurrent pterygium. Eye. 2013;27:1123–9.

  12. 12.

    Malik S, Khan MS, Basit I. Comparison of primary versus recurrent pterygium after intralesional 5-Fluorouracil. J Pak Med Assoc. 2016;66:559–62.

  13. 13.

    Bayar SA, Kucukerdonmez C, Oner O, Akova YA. Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol. 2014;34:541–7.

  14. 14.

    Nava-Castañeda A, Ulloa-Orozco I, Garnica-Hayashi L, Hernandez-Orgaz J, Jimenez Martinez MC, Garfias Y. Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. J Ocul Pharmacol Ther. 2015;31:106–13.

  15. 15.

    Khan MS, Malik S, Basit I. Effect of intralesional 5 fluorouracil injection in primary pterygium. Pak J Med Sci. 2016;32:130–3.

  16. 16.

    Singh P, Sarkar L, Sethi HS, Gupta VS. A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients. Indian J Ophthalmol. 2015;63:779–84.

  17. 17.

    Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran. 2011;49:179–83.

  18. 18.

    Lee JK, Song YS, Ha HS, Park JH, Kim MK, Park AJ. Endothelial progenitor cells in pterygium pathogenesis. Eye. 2007;21:1186–93.

  19. 19.

    Mohamed TA, Soliman W, Fathalla AM, El Refaie A. Effect of single subconjunctival injection of bevacizumab on primary pterygium: clinical, histopathological and immunohistochemical study. Int J Ophthalmol. 2018;11:797–801.

  20. 20.

    Naib-Majani W, Eltohami I, Wernert N, Watts W, Tschesche H, Pleyer U. Distribution of extracellular matrix proteins in pterygia: an immunohistochemical study. Graefes Arch Clin Exp Ophthalmol. 2004;242:332–8.

  21. 21.

    Cursiefen C, Schlötzer-Schrehardt U, Küchle M, Breiteneder-Geleff S, Alitalo K, Jackson D. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci. 2002;43:2127–35.

  22. 22.

    Schlereth SL, Neuser B, Caramoy A, Grajewski RS, Koch KR, Schrödl F, et al. Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci. 2014;55:865–72.

  23. 23.

    Detorakis ET, Zaravinos A, Spandidos DA. Growth factor expression in ophthalmic pterygia and normal conjunctiva. Int J Mol Med. 2010;25:513–6.

  24. 24.

    Dake Y, Mukae R, Soda Y, Kaneko M, Amemiya T. Immunohistochemical localization of collagen types I, II, III, and IV in pterygium tissues. Acta Histochem. 1989;87:71–4.

  25. 25.

    Kase S, Osaki M, Sato I, Takahashi S, Nakanishi K, Yoshida K, et al. Immunolocalisation of E-cadherin and beta-catenin in human pterygium. Br J Ophthalmol. 2007;91:1209–12.

Download references

Author information

Correspondence to Harminder S. Dua.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplemental Table 1

Supplemental Table 2

Supplementary Figures Legend

Supplementary Figure 1

Supplementary Figure 2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5